Mitochondrial Toxicity Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy. 2001

Cecilia M. Shikuma, and Bruce Shiramizu
John A. Burns School of Medicine, University of Hawaii at Manoa, 3675 Kilauea Avenue, Young Bldg 6th Floor, Honolulu, HI 91816, USA. shikuma@hawaii.edu; shira@pbrc.hawaii.edu

Nucleoside reverse transcriptase inhibitors result in a wide range of toxic side effects. These include lactic acidosis syndrome, myopathy, cardiomyopathy, pancreatitis, peripheral neuropathy, and possibly lipodystrophy. Despite the seemingly diverse nature of these side effects, all of these toxicities may be mediated by a common pathophysiologic mechanism, namely, mitochondrial toxicity resulting from nucleoside reverse transcriptase inhibitor-induced inhibition of DNA polymerase g. This article reviews the relevant mitochondrial biology and mechanism underlying nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical manifestations of this toxicity are reviewed followed by a discussion of clinical management.

UI MeSH Term Description Entries

Related Publications

Cecilia M. Shikuma, and Bruce Shiramizu
December 2010, Expert opinion on drug metabolism & toxicology,
Cecilia M. Shikuma, and Bruce Shiramizu
May 2014, Toxicological sciences : an official journal of the Society of Toxicology,
Cecilia M. Shikuma, and Bruce Shiramizu
June 2000, Clinical therapeutics,
Cecilia M. Shikuma, and Bruce Shiramizu
May 2008, Chemical research in toxicology,
Cecilia M. Shikuma, and Bruce Shiramizu
November 1999, AIDS (London, England),
Cecilia M. Shikuma, and Bruce Shiramizu
December 2002, The New England journal of medicine,
Cecilia M. Shikuma, and Bruce Shiramizu
March 2000, MMW Fortschritte der Medizin,
Copied contents to your clipboard!